Cargando…
Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia
SIMPLE SUMMARY: Children with T-cell leukemia (T-ALL) who experience relapse have a low chance of a cure with current therapy; so, new medicines are needed. MERTK and BCL-2 are proteins that may be therapeutic targets in children with T-ALL. In this research we tested whether treatments targeting ME...
Autores principales: | Summers, Ryan J., Jain, Juhi, Vasileiadi, Eleana, Smith, Brittany, Chimenti, Madison L., Yeung, Tsz Y., Kelvin, James, Wang, Xiaodong, Frye, Stephen V., Earp, H. Shelton, Tyner, Jeffrey W., Dreaden, Erik C., DeRyckere, Deborah, Graham, Douglas K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776749/ https://www.ncbi.nlm.nih.gov/pubmed/36551626 http://dx.doi.org/10.3390/cancers14246142 |
Ejemplares similares
-
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
por: Yan, Dan, et al.
Publicado: (2021) -
MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme
por: Sufit, Alexandra, et al.
Publicado: (2016) -
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity
por: Lee-Sherick, Alisa B., et al.
Publicado: (2020) -
MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
por: Yan, Dan, et al.
Publicado: (2022) -
The Emerging Role of TYRO3 as a Therapeutic Target in Cancer
por: Smart, Sherri K., et al.
Publicado: (2018)